MedTrace Logo

Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19

NCT04391946 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 162

Last updated 2023-05-24

No results posted yet for this study

Summary

The COVID-19 epidemic (Coronavirus Disease 2019) which is currently raging in France is an emerging infectious disease linked to a virus of the genus coronavirus (SARS-CoV-2). The first cases were reported in Wuhan, China, in late December 2019 \[1\]. Globally, it has been placed in the "pandemic" stage by the WHO since March 11, 2020. Coronavirus viruses have been responsible for epidemics in the past such as the SARS epidemic in 2002 (Syndrome Severe Acute Respiratory) linked to the SARS-CoV virus, or the epidemic of MERS (Middle East Respiratory Syndrome) that affected the Middle East in 2012.

Patients with chronic lymphocytic leukemia (CLL) / lymphocytic lymphoma or Waldenstrom Disease (WD) therefore represent a population at high risk of developing a severe form in the event of COVID-19 infection.

To date, no data is available in the literature to assess the impact of the COVID-19 epidemic in this population of patients with CLL / lymphocytic lymphoma or WD.

Conditions

  • Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease

Interventions

BEHAVIORAL

Data registry

Collection of clinical data, treatment regimens and survival data

Sponsors & Collaborators

  • Institut de cancérologie Strasbourg Europe

    collaborator OTHER

  • French Innovative Leukemia Organisation

    lead OTHER

Principal Investigators

  • Luc-Matthieu FORNECKER, Pr · French Innovative Leukemia Organisation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-14
Primary Completion
2022-03-10
Completion
2023-03-10

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04391946 on ClinicalTrials.gov